# Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer

> **NIH NIH P50** · YALE UNIVERSITY · 2023 · $2,069,846

## Abstract

YALE SPORE IN LUNG CANCER (YSILC) OVERALL SUMMARY
The Biology and Personalized Treatment of Primary and Metastatic Lung Cancer: The YSILC unites
translational scientists spanning diverse areas of cancer research to converge on addressing the challenge of
lung cancer. The goal of the YSILC is to reduce mortality from lung cancer through development of novel
therapeutics and treatment approaches that are based on an understanding of targetable biochemical and
immunological pathways involved in progression of lung cancer, acquisition of resistance, and development of
metastasis The YSILC translational research team will accomplish this objective through three projects:
Project 1: Test the hypotheses that Siglec-15 (S15) is a major immune suppressor in PD-L1/B7-H1-negative
lung cancer and that blockade of S15 can be efficacious for a subset of lung cancer patients; Project 2:
Evaluate mechanism-based approaches to counter tyrosine kinase inhibitor resistance in EGFR-mutant lung
cancer; Project 3: Targeting lung cancer metastasis and drug resistance in the central nervous system. There
are three Cores (Administrative; Biostatistics and Bioinformatics; and Biospecimen, Pathology, and Genomics)
to support the projects and their clinical aims, mechanistic studies, and evaluation of biomarkers for clinical
application. Strong Developmental Research and Career Enhancement Programs (DRP, CEP) with a
history of choosing diverse and productive projects with good outcomes are also proposed. The highly
coordinated YSILC projects, cores, and programs are focused on developing novel lung cancer therapies, with
analysis of patient samples, cell-based assays, production of human cell lines and animal models of disease
as a guide to design prospective trials that translate these innovative targeted approaches to clinical therapies.
Each of these projects has a clinical trial (either investigator-initiated or NCI-based) designed to test the
sensitivity and resistance of the new therapy with molecular correlates. The expected translational outcomes of
the program include: (1) a highly coordinated and focused development of a novel immune agent discovered
during our current SPORE research; (2) an improved understanding of genetic and epigenetic mechanisms of
resistance to EGFR therapies and how to combat it; (3) an understanding of the mechanism underlying brain
metastasis; (4) expanding the breadth of lung cancer research by developing the next generation of
investigators and encouraging established investigators in other fields to pursue studies on lung cancer
through our CEP and DRP programs.

## Key facts

- **NIH application ID:** 10690040
- **Project number:** 5P50CA196530-09
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** Roy S Herbst
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $2,069,846
- **Award type:** 5
- **Project period:** 2015-08-26 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10690040

## Citation

> US National Institutes of Health, RePORTER application 10690040, Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer (5P50CA196530-09). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10690040. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*